Causes and frequency of blindness in patients with intraocular inflammatory disease.
about
Emerging drugs for uveitisClinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essayBirdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatmentHeterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitisIntraocular Implants for the Treatment of Autoimmune UveitisUveitis- a rare disease often associated with systemic diseases and infections- a systematic review of 2619 patientsThe effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocolManagement of noninfectious posterior uveitis with intravitreal drug therapySelective and complementary use of Optical Coherence Tomography and Fluorescein Angiography in retinal practiceUrinary neopterin in idiopathic retinal vasculitisProtocol: Effect of intravitreal bevacizumab (avastin) in the treatment of macular edema: A systematic review of randomized controlled trialsReview for Disease of the Year: Epidemiology of HLA-B27 Associated Ocular Disorders.Clinical and visual outcomes of patients with uveitis in the mid-Atlantic United StatesInfectious uveitis in VirginiaIntermediate uveitis, posterior uveitis, and panuveitis in the Mid-Atlantic USA.T cell-antigen-presenting cell interactions visualized in vivo in a model of antigen-specific inflammation.Current approach in diagnosis and management of anterior uveitis.In vivo multi-modal imaging of experimental autoimmune uveoretinitis in transgenic reporter mice reveals the dynamic nature of inflammatory changes during disease progression.Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis.Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens.Angiogenin reduces immune inflammation via inhibition of TANK-binding kinase 1 expression in human corneal fibroblast cells.Novel molecular imaging approach for subclinical detection of iritis and evaluation of therapeutic success.Lack of association of C3 gene with uveitis: additional insights into the genetic profile of uveitis regarding complement pathway genes.The Association of Chemokine Gene Polymorphisms with VKH and Behcet's Disease in a Chinese Han Population.Current approach in the diagnosis and management of panuveitis.Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy.Ocular involvement in sarcoidosis.Patterns of uveitis at a tertiary referral center in southern iran.Management of chronic uveitis.Macular oedema: the role of soluble mediatorsAn update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Bevacizumab in inflammatory eye diseaseInterobserver agreement in clinical grading of vitreous haze using alternative grading scales.The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema.Spontaneous cataract absorption in patients with leptospiral uveitisOsteopontin and fibronectin levels are decreased in vitreous of autoimmune uveitis and retinal expression of both proteins indicates ECM re-modeling.Mammalian telomeric DNA suppresses endotoxin-induced uveitisWhat is new HLA-B27 acute anterior uveitis?The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics.
P2860
Q24630848-3552C1E3-26E9-4C81-9F69-8A444897296AQ26746068-DCA2C078-D941-4E97-B0C6-953705D18FB3Q26749730-76876A63-A3D7-4610-9CA4-C125500A21FAQ26796779-F1B2FBC3-6661-48C6-A529-138C5296667CQ26799168-7A8DD4F3-EBFA-4FD2-BAFB-B19573DCA6ACQ27025188-CF592432-6283-4958-B336-8A6D934466A5Q28068067-3C4F112D-52AB-4DF1-9A74-79973F8F9D53Q28074741-4EBF0BBA-4FE5-4483-A415-D7CEEFE5441FQ28074746-CBB8CA7C-7F9D-4BC6-BB9C-FB6CBA1B04E5Q28345342-D6011801-105F-4F90-9349-933FAA330BFAQ28680651-1FE67CCC-182B-4CBC-8682-B1EA63C823CBQ30250079-7E05ADBE-DC58-4D17-9D2B-FECFD894EBBAQ30278649-E9FA9113-410E-4812-8025-65966741DE3CQ30278706-4960838B-91CF-4C31-9944-A10DBC5F32F4Q30278739-6BF683A7-4219-4B87-B0F9-25E172CF99EDQ30481653-F51A25B1-4D36-4E8B-BD71-1C5488FB3C01Q30482541-E4CA0585-4675-4FE8-9D0C-6D022D8072E6Q30620955-ABF357D0-A4BF-43CF-98B4-8F7961FD1056Q33322621-49BC8A71-D007-4806-B574-C506C0DE1551Q33538277-865F09E5-0972-48C8-8A04-0E279ED1ACFAQ33594210-77362A7C-970F-4D80-9EAB-518A3B1D6274Q33617311-839C7218-34B7-49EB-9070-F12177385519Q33678499-7C9C21C5-8BB4-43FB-9ABE-08B129112E87Q33734201-922EEED5-AED8-4F93-8F3E-D7480AA5C4B6Q33737954-EA7C0B7E-1422-49DC-BCFB-7375DB91FBE5Q33760317-095D34B7-BB55-49BC-B3D2-99A8D7A377F9Q33765919-EFE86B57-FE43-4A6F-8F1E-0496175DA7DCQ33803813-FE18CAD2-AC38-406D-8DC1-2F1E44A11210Q33818906-A38D7FA7-0C9C-4198-B4E9-65C655C9F783Q33846063-7599F53B-33C5-4A63-9FB4-77D21E6F6260Q33899013-50ACDA6E-1DFC-4E9D-A7D4-F4C1679B0822Q33910781-57F177E5-B1F7-4902-BFC9-66F710D6F4E4Q33970876-160AB2BC-02B5-4A70-A87C-EE9B54561825Q34005672-1F4D1F9F-7EBA-489C-98B1-6B9973F418B1Q34033983-14999E24-750E-4AB6-BFD5-AF12207CA1C3Q34044202-AC63E801-C4FF-4AB4-B95C-9F076FADF915Q34109881-8C2E9C75-2693-46D4-8B34-DBC9F217F86EQ34121345-A38F5746-1521-49D3-9BAC-4931CD4142E9Q34172654-C0A4F08E-F64C-4520-A70E-D899A75F42AAQ34286402-D44490F9-5E04-4968-8F38-29AECCFC8D58
P2860
Causes and frequency of blindness in patients with intraocular inflammatory disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Causes and frequency of blindness in patients with intraocular inflammatory disease.
@en
Causes and frequency of blindness in patients with intraocular inflammatory disease.
@nl
type
label
Causes and frequency of blindness in patients with intraocular inflammatory disease.
@en
Causes and frequency of blindness in patients with intraocular inflammatory disease.
@nl
prefLabel
Causes and frequency of blindness in patients with intraocular inflammatory disease.
@en
Causes and frequency of blindness in patients with intraocular inflammatory disease.
@nl
P2093
P2860
P356
P1476
Causes and frequency of blindness in patients with intraocular inflammatory disease.
@en
P2093
Frits Treffers W
Kijlstra A
Suttorp-van Schulten MS
P2860
P304
P356
10.1136/BJO.80.4.332
P407
P577
1996-04-01T00:00:00Z